Stampidine - 10mM in DMSO, high purity , CAS No.217178-62-6(DMSO)

Item Number

S655771

• Specifications & Purity: 10mM in DMSO
• Storage Temp: Store at -80°C
• Shipped In: Ice chest + Ice pads

Product Description

Stampidine is a nucleoside reverse transcriptase inhibitor (NRTI) with potent and broad-spectrum anti-HIV activity. Stampidine inhibits the laboratory HIV-1 strain HTLV IIIB (B-envelope subtype) and primary clinical isolates with IC 50 s of 1 nM and 2 nM, respectively. Stampidine also inhibits NRTI-resistant primary clinical isolates and NNRTI-resistant clinical isolates with IC 50 s of 8.7 nM and 11.2 nM, respectively

In Vitro

Stampidine (7.8-1,000 μM; 24 hours) is not cytotoxic to genital tract epithelial cells. Stampidine has no effect on sperm motility in cervical mucus. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Stampidine (50-100 mg/kg; p.o.) exhibits potent antiretroviral activity in chronically feline immunodeficiency virus (FIV)-infected cats. Stampidine (100 mg/kg; p.o.) shows the average plasma C max , AUC, half-life (t 1/2 ), and mean residence time (MRT) values of 15.4 µM, 23.1 µM•h, 108.6 min and 119.4 min, respectively, in dogs. Stampidine does not cause anemia, thrombocytopenia, neutropenia, or lymphopenia suggestive of hematologic toxicity, elevations of BUN or creatinine or electrolyte disturbances suggestive of renal toxicity or metabolic abnormalities, elevations of ALT, AST, Alk in adult beagle dogs. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: SPF male or female domestic cats (2.9- 6.2 kg), with chronically FIV-infectedDosage: 50 mg/kg, 100 mg/kg Administration: Oral administration (oral bolus dose) Result: Exhibited potent antiretroviral activity. Animal Model: Male beagle dogs (10-12 kg)Dosage: 100 mg/kg (Pharmacokinetic Analysis) Administration: Oral administration Result: The estimated average plasma C max and AUC values were 15.4 µM and 23.1 µM·h, respectively. The average elimination half-life (t 1/2 ) and mean residence time (MRT) were 108.6 min and 119.4 min, respectively.

IC50& Target:IC50: 1 nM (HTLV IIIB ), 2 nM (primary clinical isolates), 8.7 nM (NRTI-resistant primary clinical isolates), 11.2 nM (NRTI-resistant primary clinical isolates)